Advanced Prostate Cancer Patients Do Not Benefit from Reolysin, Taxotere Combo, Trial Shows

Advanced Prostate Cancer Patients Do Not Benefit from Reolysin, Taxotere Combo, Trial Shows
Patients with metastatic castration-resistant prostate cancer do not benefit from the addition of Reolysin (pelareorep) to Taxotere (docetaxel), according to recent data from a Phase 2 trial. The trial (NCT01619813) failed to meet its primary endpoint of lack of disease progression at 12 weeks and secondary endpoint of overall survival, with patients receiving the combo treatment showing similar rates as

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Judith Cohen says:

    thanks for your news as always, would like to know what is the most reliable test to detect bone metastisis. Regards Judith cohen

Leave a Comment

Your email address will not be published. Required fields are marked *